Catalyst
Slingshot members are tracking this event:
Fibrocell (FCSC) to submit IND to FDA in fourth quarter of 2017 for FCX-013, a gene therapy treatment for linear scleroderma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| FCSC | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 05, 2018
Occurred Source:
http://ir.fibrocell.com/phoenix.zhtml?c=253777&p=irol-newsArticle&ID=2330235
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fcx-013, Gene Therapy, Scleroderma
